Trial Profile

The effects of subcutaneous insulin detemir on glucose flux, pharmacokinetics and brain function in type one diabetes

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 15 Jun 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin detemir (Primary)
Indications Type 1 diabetes mellitus
Focus Pharmacodynamics; Pharmacokinetics

Most Recent Events

28 Apr 2015 Accrual to date is 173% as reported by United Kingdom Clinical Research Network.
02 Nov 2012 Accrual to date is 100% as reported by United Kingdom Clinical Research Network.
02 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com